



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/107	A1	(11) International Publication Number: WO 93/02665 (43) International Publication Date: 18 February 1993 (18.02.93)
(21) International Application Number: PCT/US92/06181 (22) International Filing Date: 24 July 1992 (24.07.92) (30) Priority data: 736,352 26 July 1991 (26.07.91) US (60) Parent Application or Grant (63) Related by Continuation US 736,352 (CIP) Filed on 26 July 1991 (26.07.91) (71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only) : CONSTANTINIDES, Panayiotis, Pericleous [US/US]; 1027 North Valley Forge Road, #305, Devon, PA 19333 (US). (74) Agents: VENETIANER, Stephen et al.; SmithKline Beecham Corporation, Corporate Patents - US, UW2220, 709 Swedeland Road, P.O. Box 1538, King of Prussia, PA 19406-0939 (US). (81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE). Published <i>With international search report.</i>
(54) Title: W/O MICROEMULSIONS <div style="text-align: center;"> $\left \frac{\text{Soybean oil}}{\text{Myverol 18-99}} \right = \frac{3}{1}$ </div>		
(57) Abstract Pharmaceutically acceptable, stable, self-emulsifying (w/o) microemulsions comprising (i) a lipophilic phase comprising a long-chain fatty acid triglyceride and a low HLB surfactant, (ii) an aqueous-based hydrophilic phase containing a water-soluble therapeutic agent, and (iii) a high HLB surfactant have improved drug delivery characteristics.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

W/O MICROEMULSIONS

This invention relates to pharmaceutically acceptable water-in-oil (w/o) self-emulsifying microemulsions containing therapeutic agents, processes
5 for their preparation and their use.

Microemulsions can be defined in general as thermodynamically stable, isotropically clear dispersions of two immiscible liquids stabilized by interfacial films of surface-active molecules. The formation of
10 microemulsions usually involves a combination of three to five components, namely, an oil, water, a surfactant, a cosurfactant and an electrolyte. The tendency towards a water-in-oil (w/o) or an oil-in-water (o/w) microemulsion is dependent on the properties of the oil and the surfactant. Surfactants are conveniently classified on an empirical scale
15 known as the hydrophilic-lipophilic balance (HLB) which runs from 1 to 20. In general, (w/o) microemulsions are formed using surfactants (or emulsifiers) which have an HLB value in the range of about 3 to 6 whilst (o/w) microemulsions are formed using surfactants which have an HLB value in the range of about 8 to 18. It has long been recognized that low
20 interfacial tension contributes to the thermodynamic stability of microemulsions. To achieve this, the surfactant should preferably exhibit low solubility in both the oil and water phases, and be preferentially absorbed at the water-oil interface with concomitant lowering of interfacial tension. When interfacial tension is less than 2×10^{-2} dyn/cm,
25 a stable microemulsion can form. General reviews of microemulsions are provided by Bhargava *et al.*, Pharm. Tech., 46-53, March 1987 and Kahlweit, Science, 240, 617-621, 1988.

Microemulsions are typically substantially non-opaque, i.e. are
30 transparent or opalescent when viewed by optical microscopic means. In the undisturbed state, they are optically isotropic (non-birefringent) when examined under polarized light. The dispersed phase typically comprises particles or droplets which are normally between 5 and 200 nm in size and this gives rise to their optical transparency. These particles may be
35 spherical although other structures are feasible.

The role of the cosurfactant, usually a short-chain alcohol, is to increase the interfacial fluidity by penetrating the surfactant film and consequently creating a disordered film due to the void space among

surfactant molecules. The use of a cosurfactant in microemulsions is however optional and alcohol-free self-emulsifying emulsions and microemulsions have been described in the literature (see for instance, Pouton et al., Int., Journal of Pharmaceutics, 27, 335-348, 1985 and Osborne *et al.*, J. Disp. Sci. Tech., 9, 415-423, 1988).

There are many advantages to the use of a microemulsion over a conventional emulsion (or macroemulsion) for drug transport (delivery). Microemulsions form spontaneously, without the need for a high input of energy and are therefore easy to prepare and scale up for commercial applications; they have thermodynamic stability due to their small particle size and therefore have a long shelf life; they have an isotropically clear appearance so that they may be monitored by spectroscopic means; they have a relatively low viscosity and are therefore easy to transport and mix; they have a large interfacial area which accelerates surface reactions; they have a low interfacial tension which permits flexible and high penetrating power and, lastly, they offer the possibility of improved drug solubilization and protection against enzymatic hydrolysis. In addition, microemulsions may undergo phase inversion upon addition of an excess of the dispersed phase or in response to a temperature change and this is a property of these systems that can affect drug release from microemulsions both *in vitro* and *in vivo*. The reasons for this improved drug delivery are not however well understood.

Lipid-based microemulsions have already been proposed to enhance the bioavailability of different drugs, including peptides. Thus, GB 2 222 770-A (Sandoz Ltd) describes microemulsions and corresponding microemulsion "pre-concentrates" for use with the highly hydrophobic cyclosporin peptides. Thus, a suitable pre-concentrate comprises 1,2-propylene glycol as the hydrophilic phase, a caprylic-capric acid triglyceride as the lipophilic component and a mixture of a polyoxyethylene glycolated hydrogenated castor oil and glycerin monooleate (ratio 11:1) as the surfactant-cosurfactant. Such formulations may then be diluted with water but to give an oil-in-water rather than a water-in-oil microemulsion.

In addition, GB 2 098 865-A (Sandoz Ltd) describes topical compositions in the form of microemulsions comprising a water-immiscible organic

solvent, an emulsifier, a co-emulsifier, water and a (non-peptide) therapeutic agent. These formulations are said to have improved skin penetrating properties. Suitable organic solvents include (C₁₀₋₂₂)-fatty acid esters of (C₃₋₁₈)-alcohols such as hexyl laurate, (C₁₂₋₃₂)-hydrocarbons
5 such as squalene and mono- or diesters of glycerol with a (C₆₋₂₂)-carboxylic acid such as glyceryl caprylate (which may also act as a co-emulsifier). There is however no mention of using a long chain-fatty acid triglyceride as the oil.

10 Furthermore, US 4 712 239 (Muller *et al.*) describes multi-component systems for pharmaceutical use comprising an oil, a nonionic surfactant with an HLB value above 8 and a co-surfactant which is a partial ether or ester of a polyhydroxyl alcohol and a (C₆₋₂₂) fatty alcohol or acid, which
15 components form a "single phase" on mixing. The special properties of the system are attributed to the particular blend of surfactant and co-surfactant selected. An aqueous phase is an optional extra and the therapeutic agent may be lipophilic or hydrophilic. Such systems are said to give enhanced transdermal delivery characteristics. Although
20 examples of formulations are provided comprising medium-chain fatty acid triglycerides and medium-chain fatty acid mono- and di-glycerides, there are no corresponding examples using long-chain analogues thereof.

Finally, WO 88/00059 (Engström *et al.* and the corresponding paper, J. Dispersion Sci. Technol., 11, 479, 1990) discloses controlled release
25 compositions for biologically active materials comprising an "L2-phase" and containing an unsaturated (C₁₆₋₂₂)-, preferably C₁₈-, fatty acid monoglyceride and an unsaturated (C₁₆₋₂₂)-, preferably C₁₈-, fatty acid triglyceride, in a ratio of from 1:1 to 3:1, and a polar liquid such as water. There is however no mention of the additional inclusion of a high HLB
30 surfactant. The existence of an L2 phase had previously been described, in the context of medium-chain fatty acid components, for a water-monocaprylin-tricaprylin system by Friberg *et al.*, J. Amer. Oil Chem. Soc., 47, 149, 1970. Again, there is no mention of the additional inclusion of a high HLB surfactant.

35 We have now surprisingly found that further improved drug delivery characteristics may be obtained using (w/o) microemulsions having lipophilic phases based on a long-chain fatty acid triglyceride and a low

HLB surfactant, in combination with a high HLB surfactant and an aqueous based hydrophilic phase.

- Accordingly, the present invention provides a pharmaceutically acceptable, stable, self-emulsifying water-in-oil (w/o) microemulsion comprising:
- (a) a lipophilic phase having a long-chain fatty acid triglyceride and a low HLB surfactant;
 - (b) a high HLB surfactant;
 - (c) an aqueous hydrophilic phase; and
 - (d) a water-soluble therapeutic agent.

The accompanying drawings contain the following figures:

- Figure 1 illustrates a pseudo-ternary phase diagram reading of a microemulsion system containing an oil and a low HLB surfactant in a fixed ratio X, a high HLB surfactant and an aqueous phase;
- Figure 2 illustrates a pseudo-ternary phase diagram of the microemulsion system soybean oil/MYVEROL 18-99 as the oil/low HLB surfactant in a ratio of 3 to 1, Tween 80 as the high HLB surfactant and water as the aqueous phase;
- Figure 3 illustrates a pseudo-ternary phase diagram of the microemulsion system soybean oil/MYVEROL 18-99 as the oil/low HLB surfactant in a ratio of 3 to 1, Tween 80 as the high HLB surfactant and saline as the aqueous phase;
- Figure 4 illustrates a pseudo-ternary phase diagram of the microemulsion system soybean oil/ARLACEL 186 as the oil/low HLB surfactant in a ratio of 3 to 1, Tween 80 as the high HLB surfactant and water as the aqueous phase;
- Figure 5 illustrates a pseudo-ternary phase diagram of the microemulsion system soybean oil/sorbitan sesquioleate as the oil/low HLB surfactant in a ratio of 3 to 1, Tween 80 as the high HLB surfactant and water as the aqueous phase;
- Figure 6 illustrates a pseudo-ternary phase diagram of the microemulsion system soybean oil/sorbitan monooleate as the oil/low HLB surfactant in a ratio of 3 to 1, Tween 80 as the high HLB surfactant and water as the aqueous phase; and

SUBSTITUTE SHEET

Figure 7 illustrates a pseudo-ternary phase diagram of the microemulsion system soybean oil/sorbitan monooleate as the oil/low HLB surfactant in a ratio of 4 to 1, Tween 80 as the high HLB surfactant and water as the aqueous phase.

5

Suitable long-chain fatty acid triglycerides for use in the present invention may be of natural, semi-synthetic or synthetic origin and may include blends of different long-chain fatty acid triglycerides. The term "long-chain fatty acid" as used herein refers to a fatty acid which may be

10 saturated, mono-unsaturated or poly-unsaturated, having from 12 to 22, preferably 14 to 18, carbon atoms which may be branched or unbranched, preferably unbranched, and which may be optionally substituted. Certain neutral, natural or hydrogenated plant, vegetable and fish oils such as shark oil, olive oil, sesame oil, peanut oil, natural and hydrogenated castor

15 oils, safflower oil, sunflower oil and soybean oil provide convenient sources of long-chain fatty acid triglycerides. Soybean oil consists of oleic acid (25%), linoleic acid (54%), linolenic acid (6%), palmitic acid (11%) and stearic acid (4%) triglycerides whilst safflower oil consists of oleic acid (13%), linoleic acid (76%), stearic acid (4%) and palmitic acid (5%)

20 triglycerides. Suitably in such long-chain fatty acid triglycerides, the major fatty acid components are C₁₈-saturated, monounsaturated or polyunsaturated fatty acids, preferably C₁₈-monounsaturated or polyunsaturated fatty acids.

25 Suitable low HLB surfactants for use in the present invention include long-chain fatty acid monoglycerides, optionally comprising up to 10% (w/w) of a long-chain fatty acid diglyceride and/or a small amount by weight of a free long-chain fatty acid. The mono- and di-glycerides may each include blends of different long-chain fatty acid mono- and di-

30 glycerides. Suitable long-chain fatty acid monoglycerides include glycerol monooleate, glycerol monopalmitate and glycerol monostearate. Suitable commercially-available examples of such include the products available under the trade names MYVEROL, such as MYVEROL 18-99, MYVATEX and MYVAPLEX, respectively, from Eastman Kodak Chemicals,

35 Rochester, New York. A further useful long-chain fatty acid monoglyceride-containing product is ARLACEL 186 (available from ICI Americas Inc.) which includes, in addition to glycerol monooleate, propylene glycol (10%). The main fatty acids of MYVEROL 18-99 are oleic

acid (61%), linoleic acid (21%), linolenic acid (9%) and palmitic acid (4%). Suitably in such long-chain monoglycerides, the major fatty acid component is a C₁₈-saturated, monounsaturated or polyunsaturated fatty acid, preferably a C₁₈-monounsaturated or polyunsaturated fatty acid. In addition, diacetylated versions of the monoglycerides such as the product available under the trade name MYVATEX SMG are also useful. Further suitable low HLB surfactants for use in the present invention include sorbitan long-chain fatty acid esters such as sorbitan monooleate, available commercially under the trade names SPAN 80 and ARLACEL 80 and sorbitan sesquioleate, available commercially under the trade names SPAN 83 and ARLACEL 83. Suitably the low HLB surfactant will have an HLB value in the range of about 2.5 to 6. The HLB values of the products MYVEROL 18-99, ARLACEL 80, ARLACEL 83 and ARLACEL 186 are respectively 3.7, 4.3, 3.7 and 2.8.

Suitable combinations of long-chain fatty acid triglycerides and low HLB surfactants include soybean oil or safflower oil and glycerol monooleate, sorbitan monooleate or sorbitan sesquioleate.

The use in a self-emulsifying (w/o) microemulsion according to the present invention of a low HLB surfactant which is a long-chain fatty acid monoglyceride optionally containing a long-chain fatty acid diglyceride or which is a sorbitan long-chain fatty acid ester as hereinbefore defined and which is a component of the lipophilic phase provides for reduced droplet size and this is believed to aid in the absorption of the therapeutic agent.

Suitable high HLB surfactants for use in the present invention include non-ionic surfactants such as (a) polyoxyethylene fatty acid esters, for example polyoxyethylene stearic acid esters of the type available under the trade name MYRJ (ICI Americas, Inc.), for instance the product MYRJ 52 (a polyoxyethylene 40 stearate); (b) polyoxyethylene-sorbitan fatty acid esters (polysorbates), for example the mono- and tri-lauryl, palmityl, stearyl and oleyl esters, for instance the polyoxyethylene sorbitan monooleates available under the trade name of TWEEN (ICI Americas Inc.), such as TWEEN 20, 21, 40, 60, 61, 65, 80, 81 and 85, of which class TWEEN 80 is especially preferred; (c) polyoxyethylene glycol long-chain alkyl ethers, such as polyoxyethylated glycol lauryl ether; and (d) polyoxyethylene glycol long-chain alkyl esters, such as PEG-monostearate.

For use herein, the high HLB surfactant preferably has an HLB value in the range of 13 to 20. The products MYRJ 52 and TWEEN 80 have HLB values of 16.9 and 15.0 respectively.

- 5 Suitably, the blend of low and high HLB surfactants will have an HLB value in the range of from about 5 to about 8.

As used herein, the term "therapeutic agent" (hereinafter referred to as "drug") refers to any compound which has biological activity, is soluble in
10 the hydrophilic phase and has an HLB value of at least that of the high HLB surfactant used in the formulation, to ensure that the drug is preferentially dissolved in the hydrophilic rather than the lipophilic phase. Suitable drugs include both peptides and non-peptides. Suitable peptides include not only small peptides but also larger peptides or
15 polypeptides and proteins. Suitable such peptides preferably have a molecular weight from about 100 to 10,000, more preferably from about 100 to about 6,000. Especially preferred peptides have from 2 to 35 amino acid moieties. Higher molecular weight polypeptides, with a molecular weight above 10,000 and up to about 50,000, may also be accommodated in
20 microemulsions of the present invention.

Suitable small peptides have from about 2 to about 10, more preferably from about 2 to about 6 amino acid moieties. Preferred small peptides include the fibrinogen receptor antagonists (RGD containing peptides)
25 which are tetrapeptides with an average molecular weight of about 600. These peptide antagonists are highly potent platelet aggregation inhibitors at plasma levels as low as 1 pmol/ml. Preferred fibrinogen antagonists include the peptide cyclo(S,S)-N^a-acetyl-Cys-(N^a-methyl)Arg-Gly-Asp-Pen-NH₂ (Ali *et al.*, EP 0 341 915, whose disclosure is herein
30 incorporated by reference in its entirety) and the peptide cyclo(S,S)-(2-mercapto)benzoyl-(N^a-methyl)Arg-Gly-Asp-(2-mercapto)phenylamide (EP 0 423 212, whose disclosure is herein incorporated by reference in its entirety). Other fibrinogen antagonists useful in the present invention are those peptides disclosed by Pierschbacher *et al.*, WO 89/05150
35 (US/88/04403); Marguerie, EP 0 275 748; Adams *et al.*, U.S. 4,857,508; Zimmerman *et al.*, U.S. 4,683,291; Nutt *et al.*, EP 0 410 537, EP 0 410 539, EP 0 410 540, EP 0 410 541, EP 0 410 767, EP 0 410 833, EP 0 422 937 and EP 0 422 938; Ali *et al.*, EP 0 372 486; Ohba *et al.*, WO 90/02751

(PCT/JP89/00926); Klein *et al.*, U.S. 4,952,562; Scarborough *et al.*, WO 90/15620 (PCT/US90/03417); Ali *et al.*, PCT/US90/06514 and PCT/US92/00999; the peptide-like compounds disclosed by Ali *et al.*, EP 0 381 033 and EP 0 384 362; and the RGD peptide cyclo-N^a-acetyl-Cys-Asn-
5 Dtc-Amf-Gly-Asp-Cys-OH (in which Dtc is 4,4'-dimethylthiazolidine-5-carboxylic acid and Amf is 4-aminomethylphenylalanine).

The RGD peptide may be usefully included in the microemulsion formulation in an amount up to about 300mg/g of the hydrophilic phase or
10 from 0.1 to 10 mg/g of the formulation.

Other peptides useful in the present invention include, but are not limited to, other RGD containing peptides such as those disclosed by Momany, U.S. 4,411,890 and U.S. 4,410,513; Bowers *et al.*, U.S. 4,880,778, U.S.
15 4,880,777, U.S. 4,839,344; and WO 89/10933 (PCT/US89/01829); the peptide Ala-His-D-Nal-Ala-Trp-D-Phe-Lys-NH₂ (in which Nal represents β-naphthylalanine) and the peptides disclosed by Momany, U.S. 4,228,158, U.S. 4,228,157, U.S. 4,228,156, U.S. 4,228,155, U.S. 4,226,857, U.S. 4,224,316, U.S. 4,223,021, U.S. 4,223,020, U.S. 4,223,019 and U.S.
20 4,410,512.

Other suitable peptides include hexapeptides such as the growth hormone releasing peptide (GHRP) His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, (Momany, US 4,411,890, the disclosure of which is herein incorporated by reference
25 in its entirety). This may be usefully included in microemulsions at up to 150mg/g of the hydrophilic phase and from 0.1 to 5mg/g of the formulation.

Suitable polypeptides and proteins for use in microemulsions of the present invention include insulin, calcitonin, elcatonin, calcitonin-gene
30 related peptide and porcine somatostatin as well as analogs and homologs thereof. Other suitable larger polypeptides include those disclosed by Pierschbacher *et al.*, U.S. 4,589,881 (>30 residues); Bittle *et al.*, U.S. 4,544,500 (20-30 residues); and Dimarchi *et al.*, EP 0 204 480 (>34
35 residues).

Other type of compounds useful in the present invention include analogs or homologs of LHRH which display potent LH releasing activity or inhibit

the activity of LHRH; analogs or homologs of HP5 which possesses hematopoietic activity; analogs or homologs of endothelin which possess hypotensive activity; analogs or homologs of enkephalin which have antinociceptive activity; analogs or homologs of cholecystokinin; analogs or homologs of atrial natriuretic factor; peptidergic antineoplastic agents; analogs or homologs of gastrin releasing peptide; analogs or homologs of somatostatin; gastrin antagonists; bradykinin antagonists; neurotensin antagonists; bombesin antagonists; oxytocin agonists and antagonists; vasopressin agonists and antagonists; hirudin analogs and homologs; analogs and homologs of the cytoprotective peptide-cyclolinopeptide; alpha MSH analogs; analogs, and homologs of MSH releasing factor (Pro-Leu-Gly-NH₂); peptides which inhibit collagenase; peptides which inhibit elastase, peptides which inhibit renin; peptides which inhibit HIV protease; peptides which inhibit angiotensin converting enzyme; peptides which inhibit chymases and tryptases and peptides which inhibit blood coagulation enzymes.

Other suitable drugs include non-peptide therapeutic agents such as antibiotics, antimicrobial agents, antineoplastic agents, cardiovascular and renal agents, antiinflammatory, immunosuppressive and immunostimulatory agents and CNS agents.

Preferably, the drug is a peptide such as a fibrinogen receptor antagonist peptide (an RGD peptide), GHRP (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂), a vasopressin, a calcitonin or an insulin, more preferably GHRP or the RGD peptides cyclo(S,S)-N^a-acetyl-Cys-(N^a-methyl)Arg-Gly-Asp-Pen-NH₂ or cyclo(S,S)-(2-mercapto)benzoyl-(N^a-methyl)Arg-Gly-Asp-(2-mercapto)phenylamide.

In a preferred aspect, the present invention provides microemulsions comprising a peptide which may be orally administered and which will retain biological activity, thereby overcoming the disadvantages of earlier formulations in which the bioavailability of the peptide has been less than satisfactory. In particular, the present invention provides formulations which by their nature permit the preparation and administration of a peptide in sufficiently high concentration to allow not only convenient oral administration but also adequate bioavailability of the peptide.

For a water-soluble drug, the degree of incorporation into the (w/o) microemulsions of the present invention is limited by its solubility in the hydrophilic phase. The ionic strength and pH (within the range 3 to 10) may be adjusted to aid dissolution, without compromising the integrity of the microemulsion.

The aqueous hydrophilic phase suitably comprises water or an isotonic saline solution and may also include any pharmaceutically acceptable solvent which is non-miscible with the lipophilic phase.

In a preferred aspect, it has been found that in microemulsions of the present invention, the use of a mono- or polyhydroxyalcohol co-surfactant, such as ethanol, butanol or propylene glycol, as the major component of the hydrophilic phase may be avoided. This has the advantage of not only mitigating the stability and processing difficulties associated with the use of such but also reducing the concomitant stomach and duodenum irritation. Accordingly, the hydrophilic phase of microemulsions of the present invention may be essentially aqueous and comprise less than 10%, preferably less than 5% and more preferably less than 2% by weight of the phase of an alcohol.

It will be readily appreciated by the skilled person that not all blends of a long-chain fatty acid triglyceride, low and high HLB surfactants and hydrophilic phase will yield stable, self-emulsifying microemulsions within the scope of the present invention. Appropriate ratios may, however, be readily determined by the skilled man with the aid of a phase diagram such as that illustrated in Fig. 1. As the system comprises four components *viz* a long-chain fatty acid triglyceride (oil), a low HLB surfactant, a high HLB surfactant and an aqueous/hydrophilic phase, a pseudo-ternary phase diagram is employed. In this, the ratio of two components such as the oil and the low HLB surfactant is kept constant so that there are only three variables, each of which can then be represented by one side of the triangle.

Thus, in Fig. 1, (1) represents the mixture of the oil and the low HLB surfactant, at a fixed ratio X, (2) the hydrophilic (aqueous) phase and (3) the high HLB surfactant. By way of example, the point "A" represents a

mixture having 50% oil plus low HLB surfactant, 20% aqueous phase and 30% high HLB surfactant.

5 The regions of the phase diagram in which microemulsion according to the present invention exist may be determined by titrating a mixture of the oil and low HLB surfactant (in a fixed ratio) against the high HLB surfactant and the hydrophilic phase, noting points of phase separation, turbidity and transparency. Clear, transparent formulations are indicative of the formation of a stable microemulsion. Liquid and gel formulations may be
10 obtained at room temperature according to the specific nature of the components employed.

Once stable transparent systems are obtained, simple tests, such as dye solubilization, dispersibility in water and conductivity measurements may
15 be used to determine whether the microemulsion is an (o/w)- or a (w/o)-type. A water-soluble dye will disperse in an (o/w) microemulsion whilst it will remain in its original form in a (w/o) microemulsion. Likewise, (o/w) microemulsions are generally dispersible in water whereas (w/o) microemulsions are generally not. In addition, (o/w) microemulsions
20 conduct electricity whereas (w/o) do not. The isotropic nature of the system may be confirmed by examination thereof under polarised light. The microemulsions being micellar in nature are isotropic and therefore non-birefringent when examined under polarised light.

25 From this phase diagram, appropriate percentages may then be read off. The process may then be repeated for other ratios of oil to low HLB surfactant so that an overall picture may be obtained.

A representative pseudo-ternary phase diagram for systems containing a
30 long-chain fatty acid triglyceride (soybean oil) and a low HLB surfactant (MYVEROL 18-99) (ratio 3:1), a high HLB surfactant (TWEEN 80) and water as the hydrophilic (aqueous) phase is shown in Figure 2. The mixture of oil plus the low HLB surfactant is indicated as component (1), water as component (2) and the high HLB surfactant as component (3).
35 The phase diagram is a "partial" phase diagram as the study was limited to those relative amounts of the various components in which microemulsions were expected to be found. This system produces a range of clear, transparent microemulsions (the microemulsion existence field)

which are shown in the phase diagram as the shaded area. The microemulsion existence field was essentially unchanged when water was replaced by saline, as shown in Fig. 3.

- 5 In general, stable clear, transparent liquid microemulsions were obtained when the oil plus low HLB surfactant was present in the range from about 70 to about 95% , the high HLB surfactant from about 5 to about 25% and the water less than 5% (w/w) of the microemulsion.
- 10 By this process of constructing a representative range of phase diagrams, it has been possible to determine appropriate quantities of the various components which will lead to stable, self-emulsifying microemulsions falling within the present invention.
- 15 Suitably, the long-chain fatty acid triglyceride and the low HLB surfactant together comprise from about 70 to about 95%, preferably about 85 to about 95%, (w/w) of the microemulsion. The long-chain fatty acid triglyceride and the low HLB surfactant may be combined and mixed at various ratios. Useful (w/o) microemulsions may be obtained when the
- 20 ratio of long-chain fatty acid triglyceride to low HLB surfactant is in the range of about 4:1 to about 2:1, preferably about 4:1 to about 3:1.

Suitably, the high HLB surfactant is present in the range of about 5 to about 25%, preferably about 7.5 to about 15% (w/w) of the microemulsion.

25

Suitably, the hydrophilic phase comprises from just greater than 0 to about 10%, preferably from about 0.1 to about 5%, more preferably from about 2 to about 5% (w/w) of the microemulsion.

- 30 It will be readily appreciated by the skilled person that, in general, an increase in the relative amount of high HLB surfactant will have to be matched by an increase in the relative amount of hydrophilic phase.

- 35 In preferred microemulsions of the present invention, the lipophilic phase comprises from about 70 to 95%, suitably 85 to 95%, the high HLB surfactant from about 5 to 25%, suitably 7.5 to 15% and the hydrophilic phase less than 10%, suitably from 0.1 to 5% (w/w) of the microemulsion.

Within such microemulsions, the ratio of long-chain fatty acid triglyceride to low HLB surfactant is between 4:1 and 2:1, suitably between 4:1 and 3:1.

- 5 The microemulsions of the present invention are substantially non-opaque, that is they are transparent or opalescent when viewed by optical microscopic means. In their undisturbed state, they are optically isotropic (non-birefringent) when examined under polarized light. They generally exhibit excellent stability at low and ambient temperatures, without
10 phase separation, clouding or precipitation, even over prolonged periods of time. The formulations may be stored in a stable form at various temperatures, such as at 4°C, ambient temperature, 37°C and 50°C, preferably at 4°C or ambient temperatures. Peptide-containing microemulsions of the present invention exhibit a similar stability (shelf
15 life) profile to that of the corresponding peptide-free microemulsions. Stable (w/o) microemulsions may be formed when the pH of the aqueous phase varies from a pH of approximately 3 to about 10, a property that can be beneficial for drugs exhibiting higher solubility at low or high pH. Microemulsions with a relatively higher amount of a high HLB surfactant
20 such as TWEEN 80 tend to be more viscous due to the greater viscosity of this material.

- Preferably, the diameter of droplets or particles of microemulsions of the present invention, measured, for instance, as the number-average
25 diameter by laser light scattering techniques, is less than 150 nm, more preferably less than 100 nm, yet more preferably less than 50 nm and most preferably in the range 5 to 35 nm.

- The various phases may optionally contain further ingredients, such as,
30 but not limited to:
- (i) lipids, such as phospholipids, in particular lecithins, such as soya bean lecithins, egg lecithin or egg phosphatide, cholesterol or oleic acid;
 - (ii) antioxidants such as n-propyl gallate, butylated hydroxyanisole (BHA) and mixed isomers thereof, d- α -tocopherol and mixed isomers thereof,
35 ascorbic acid, propylparaben, methylparaben and citric acid (monohydrate);
 - (iii) bile salts, for instance as their alkali metal salts, such as sodium taurocholate;

- (iv) stabilizers, such as hydroxypropyl cellulose;
- (v) antimicrobials, such as benzoic acid (sodium salt);
- (vi) dioctylsuccinate, di-octylsodium sulfosuccinate or sodium lauryl sulfate; and
- 5 (vii) protease inhibitors such as aprotinin.

The microemulsions of the present invention form spontaneously or substantially spontaneously when their components are brought into contact, that is without the application of substantial energy supply, for instance in the absence of high shear energy such as imparted by
10 homogenization and/or microfluidization or other mechanical agitation. Accordingly the microemulsions may be readily prepared by the simple process of admixing appropriate quantities, with gentle hand mixing or stirring, if necessary, to ensure thorough mixing. Preferably, the drug is
15 dissolved in the hydrophilic phase, either directly or by dilution of a stock solution thereof and this may then be added to a pre-mixed combination of the oil and the low HLB surfactant with mixing, followed by the high HLB surfactant or *vice versa*. Alternatively, a drug-free microemulsion may be initially prepared by admixing the oil, low and high HLB surfactants and
20 some (drug-free) hydrophilic phase to which may then be added drug dissolved in hydrophilic phase. If necessary, higher temperatures (40-60°C) may be used to assist the solubilization of all of the components during the preparation of the microemulsion. Formulation at ambient temperature is, however, preferred for thermolabile active ingredients,
25 such as peptides.

Microemulsions of the present invention are pharmaceutical compositions which comprise a therapeutic agent and are therefore intended for use in therapy, for administration to animals, including man.

30

Accordingly, in a further aspect, the present invention provides a method of treatment which comprises administering an effective amount of a microemulsion as hereinbefore defined to a patient in need thereof.

35

It will be recognized by one of skill in the art that the amount of drug required for therapeutic effect on administration will, of course, vary with the agent chosen, the nature and severity of the condition and the animal undergoing treatment, and is ultimately at the discretion of the physician.

- Furthermore, the optimal quantity and spacing of individual dosages of a drug will be determined by the nature and extent of the condition being treated, the form, route and site of administration, the particular patient being treated and that such optima can be determined by conventional techniques. It will also be appreciated that the optimal course of treatment, that is, the number of doses given, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
- 10 The present invention also provides for the use of a long-chain fatty acid triglyceride, a low HLB surfactant, a high HLB surfactant, a therapeutic agent and a hydrophilic phase as hereinbefore defined in the manufacture of a medicament.
- 15 Microemulsions of the present invention may be used for oral, topical, rectal, intra-vaginal or other forms of systemic administration and accordingly will be presented in forms suitable for such. Thus for instance, microemulsions intended for oral administration may be presented in soft gelatin capsules whilst the viscosity characteristics of some of the microemulsions make them suitable for direct topical application. Compositions adapted for oral or topical administration are especially preferred.
- 20 The microemulsions of the present invention without a drug are novel and useful as precursors to drug-containing microemulsions. Accordingly, in a further aspect, the present invention provides a stable, self-emulsifying water-in-oil microemulsion comprising:
- (a) a lipophilic phase having a long-chain fatty acid triglyceride and a low HLB surfactant; (b) a high HLB surfactant; and (c) an aqueous hydrophilic phase in which each of (a), (b) and (c) are as hereinbefore defined and pharmaceutically acceptable.
- 30

The invention will now be illustrated by, but not limited to, the following descriptions (drug-free microemulsions) and examples (drug-containing microemulsions) and biological examples.

35

DESCRIPTIONS

Description 1 - Phase Diagrams (partial) for Representative Microemulsions

Representative pseudo-ternary partial phase diagrams (fig. 2 and 3) for the system soybean oil, MYVEROL 18-99 (ratio 3:1), TWEEN 80 and water or saline have already been described elsewhere. This study was extended to other systems in which the oil and the high HLB surfactant were kept constant whilst the low HLB surfactant, the ratio thereof to the oil and the aqueous phase were varied, as shown in the table 1:

Table 1 - Systems for phase diagrams

Description no. (fig.)	Low HLB surfactant	Ratio oil to low HLB surfactant	Aqueous
1a/(fig.2)	MYVEROL 18-99	3:1	deionised water
1b/(fig.3)	MYVEROL 18-99	3:1	saline
1c/(fig.4)	ARLACEL 186	3:1	deionised water
1d/(fig.5)	ARLACEL 83	3:1	deionised water
1e/(fig.6)	ARLACEL 80	3:1	deionised water
1f/(fig.7)	ARLACEL 80	4:1	deionised water

The various components were weighed out individually and then mixed at a temperature between 40 and 50°C. The relative order of addition would appear to be unimportant. For components such as MYVEROL 18-99 which has a melting point of about 42°C and is therefore a solid at room temperature, it was useful to premelt at an appropriate temperature, prior to addition to assist in complete mixing and solubilisation. Heating at about 50°C was also usefully be employed during subsequent mixing. Further equilibration of the microemulsion for a 24 h period was found to improve the stability of some microemulsions.

The regions of the phase diagram in which microemulsions according to the present invention exist were determined by titrating a mixture of the oil and low HLB surfactant (in a fixed ratio) against the high HLB surfactant and the aqueous phase, noting points of phase separation, turbidity and transparency. Clear, transparent formulations are indicative of the formation of a stable microemulsion.

Representative partial phase diagrams with emphasis on the microemulsion-existence field are shown as figure 2 and 3 for the MYVEROL 18-99 system. Similar phase diagrams were also obtained for the other systems containing other low HLB surfactant and these are shown as Figures 4 to 7. Clear, transparent microemulsions were obtained in the shaded areas on the phase diagrams (the microemulsion existence field). When examined under polarised light, non-birefringent behaviour was observed. These microemulsions were also found to have extremely low electrical conductance. In general, replacing water by saline had no effect on the microemulsion existence field, other than small changes in the boundary region. Changing the ratio of oil to low HLB surfactant from 3:1 to 4:1 resulted in the formation of a narrower field, due to the reduced amount of low HLB surfactant. The microemulsions were however otherwise similar to those obtained in the "3:1" systems.

The ranges of the components for selected systems in which microemulsion fields were observed is given in table 2:

Table 2

Description no.	lipophilic phase %	High HLB surfactant %	hydrophilic phase %
1a	70 to 90	5 to 25	<10
1b	70 to 90	5 to 25	<10
1c	80 to 95	5 to 15	<10

These phase diagrams show that microemulsions within the scope of the present invention are obtained for ratios of long-chain fatty acid triglyceride to low HLB surfactant ranging from 4:1 to 3:1. Clear and transparent liquid microemulsions similar to those described above were also obtained at oil to low HLB surfactant ratios of 2:1.

Various physical characteristics of the microemulsions hereinbefore described are given in the table 3. All the microemulsions had oil plus low HLB surfactant (3:1, 87%), high HLB surfactant (10%) and aqueous (3%).

Table 3 - Physical Properties of Microemulsions

Description no.	Viscosity ^a (centiPoise)	Refractive index ^a	Conductance ^b (micromhos/cm)
2	110.7	1.471	0.131
1e	129.3	1.471	0.130
1g	145.3	1.472	0.130
1d	125.1	1.469	0.177
Oleic Acid ^c	23.4 (25.6)	1.4582 (1.4583)	ND
Deionized Water	ND	ND	2.67
Saline	ND	ND	13400

^a aqueous phase = water

5 ^b aqueous phase = saline

^c the viscosity and refractive index values shown in parentheses are from the CRC Handbook of Chemistry and Physics, 60th Edition.

- 10 Measurement of particle diameter by laser light scattering of the representative microemulsions showed that they were mostly in the range 5 to 30nm and had a high degree of homogeneity (polydispersity in the range 0.05 to 0.20). This was not significantly affected by the inclusion of a peptide (as in example 1a, at 1 or 3mg/g formulation).
- 15 Microemulsions comprising glycerol monooleate (MYVEROL 18-99, mp about 42°C) as the low HLB surfactant formed gels at low temperature (4°C) which upon reequilibration at room temperature or 37°C returned to clear, transparent microemulsions. After several weeks storage at room temperature, some precipitation and solidification was observed. This was
- 20 however reversed by warming up to 37 or 50°C. At these temperatures, the microemulsions were stable for over one month, without any precipitation and/or phase separation. In corresponding microemulsions still containing glycerol monooleate but using the product MYVEROL 18-99 rather than ARLACEL 186, similar one month storage stability was
- 25 observed at 37 and 50°C. At 4°C, a gel was formed but this had much better long-term stability after returning to room temperature. Excellent storage characteristics were also observed for microemulsions comprising

either sorbitan monooleate (ARLACEL 80) or sorbitan sesquioleate (ARLACEL 83) as the low HLB surfactant.

Description 2 - (w/o) microemulsion

5

A representative water-in-oil microemulsion was prepared on a 5g scale using the following:

	Soybean oil and MYVEROL 18-99 (ratio 3:1)	87%
10	TWEEN 80	10
	Deionised water or saline	3

MYVEROL 18-99 was premelted on a water bath before being added to soybean oil in a vial on a hot plate stirrer maintained at 50°C, with gentle stirring. This mixture was then added to a stirred mixture of TWEEN 80 and water or saline to form a clear transparent (w/o) microemulsion . Additional equilibration at 50°C was found to improve stability. At low to ambient temperatures, the liquid formulation became a gel but this was reversed on warming to higher temperature.

20

EXAMPLES

For further studies on microemulsions incorporating a drug, an optimal formulation was selected from about the centre of the microemulsion field of the phase diagrams hereinbefore described. This formulation comprised soybean oil plus low HLB surfactant (87%), TWEEN 80 (10%) and a variable aqueous phase (3%).

These microemulsions were generally formulated by initially preparing the drug-containing hydrophilic phase, either by dissolving the appropriate amount of drug in the appropriate amount of water or, more preferably, using a stock solution which was then further diluted if so required, with vortex stirring if necessary to obtain complete dissolution. The hydrophilic phase containing the drug was then added to the appropriate amounts (by weight) of a mixture of the oil and the low HLB surfactant, to which was then added the high HLB surfactant, with gentle stirring (magnetic hot plate stirrer). Alternatively, the hydrophilic phase containing the drug was added to the high HLB surfactant and following

30

35

upon complete mixing, this was added to the oil plus low HLB surfactant mixture. If necessary, the drug-containing microemulsion was then diluted with the corresponding drug-free microemulsion to adjust the concentration of the drug. Batches were routinely prepared on a 5 or 10 g scale. In addition larger scale (50 to 500g) batches were also prepared.

Following the standard procedure outlined above, the following drug-containing microemulsions were prepared, as shown in the table 4:

10 **Table 4 - Examples of drug-containing microemulsions**

Example	Drug	Drug conc. mg/g form.	high HLB surfactant
1a	RGD peptide ^a	1-6	MYVEROL 18-99
1b	RGD peptide ^a	6	ARLACEL 80
1c	RGD peptide ^a	6	ARLACEL83
1d	RGD peptide ^a	6	ARLACEL186
2	GHRP ^b	3.0	MYVEROL 18-99
3	vasopressin ^c	0.06	ARLACEL186
4a	calcitonin ^d	0.02	ARLACEL186
4b	calcitonin ^d	0.09	ARLACEL186
5a	insuline ^e	0.15 (37 IU)	ARLACEL186
5b	insuline ^e	0.38 (92 IU)	ARLACEL186

Footnotes to table

- ^a cyclo(S,S)-(2-mercapto)benzoyl-(N^a-methyl)-Arg-Gly-Asp-(2-mercapto)-phenylamide (MW of about 650), aq. = saline;
- 15 ^b His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ (MW of about 850), aq. = isotonic soln containing acetic acid and NaCl at pH 5.0;
- ^c Val-Asp-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly- NH₂ (MW of about 1300) (ICN Biochemicals), aq. = saline;
- 20 ^d salmon calcitonin (contains 32 amino acids, MW of about 3500) (ICN Biochemicals), aq. = saline; and

^e polypeptide with a MW of about 6000 (ICN Biochemicals), aq. = phosphate-buffered saline.

BIOLOGICAL EXAMPLES

5

Biological Example 1- Assessment of GI Irritation

Using standard methodology (Szabo *et al.*, J. Pharmacol. Methods, **13**, 59-66, 1985), a drug-free microemulsion comprising soybean oil and one of
10 MYVEROL 18-99, ARLACEL 80, ARLACEL 83 or ARLACEL186 (ratio 3:1) (87%), TWEEN 80 (10%) and saline (3%) was assessed for its potential to cause GI irritation in rats. After oral dosing (3.3 ml/kg), the mucosal surfaces of both the stomach and duodenum were found to be free of any lesions, even under microscopic examination.

15

Biological Example 2 - Demonstration of *in vivo* activity of RGD peptide delivered by a microemulsion

The *in vivo* activity of microemulsions of containing soybean oil and one of
20 MYVEROL 18-99, ARLACEL 80, ARLACEL 83 or ARLACEL186 (ratio 3:1) (87%), TWEEN 80 (10%) and saline (3%) and the RGD peptide of example 1a (6mg/g formulation) was demonstrated in a standard platelet aggregation assay using dogs (Samanen *et al.*, Med Chem., **34**, 3114-3125, 1991). Following oral dosing of the microemulsion containing the peptide
25 (in a gelatin capsule) at 3 mg/kg (0.5 ml/kg microemulsion), inhibition was observed which was, in general, more pronounced and, in some cases, more sustained than that observed in a corresponding control experiment in which the RGD peptide was dosed as a saline solution.

Claims

1. A pharmaceutically acceptable, stable, self-emulsifying water-in-oil microemulsion comprising:
 - 5 (a) a lipophilic phase having a long-chain fatty acid triglyceride and a low HLB surfactant;
 - (b) a high HLB surfactant;
 - (c) an aqueous hydrophilic phase; and
 - (d) a water-soluble therapeutic agent.
- 10 2. A microemulsion as claimed in claim 1 in which the major fatty acid components of the long-chain fatty acid triglyceride are C₁₈-saturated, monounsaturated or polyunsaturated fatty acids.
- 15 3. A microemulsion as claimed in claim 1 or 2 in which the low HLB surfactant is (a) a sorbitan long-chain fatty acid ester or (b) a long-chain fatty acid monoglyceride optionally comprising up to 10% (w/w) of a long-chain fatty acid diglyceride and/or a small amount by weight of a free long-chain fatty acid.
- 20 4. A microemulsion as claimed in claim 3 in which the long-chain fatty acid is a C₁₈-saturated, monounsaturated or polyunsaturated fatty acid.
- 25 5. A microemulsion as claimed in any one of claims 1 to 4 in which the high HLB surfactant is a polyoxyethylene fatty acid ester, a polyoxyethylene-sorbitan fatty acid ester, a polyoxyethylene glycol long-chain alkyl ether or a polyoxyethylene glycol long-chain alkyl ester.
- 30 6. A microemulsion as claimed in any one of claims 1 to 5 in which the therapeutic agent is a peptide.
- 35 7. A microemulsion as claimed in any one of claims 1 to 6 in which the lipophilic phase comprises from 70 to 95%, the high HLB surfactant from 5 to 25% and the hydrophilic phase less than 10% and in which the ratio of long-chain fatty acid triglyceride to low HLB surfactant is between 4:1 and 2:1.

8. A self-emulsifying microemulsion optionally comprising a water-soluble therapeutic agent in which the relative proportions of the following components:
- (1) a lipophilic phase comprising a long-chain fatty acid triglyceride or a blend of long-chain fatty acid triglycerides and a low HLB surfactant or a blend of low HLB surfactants;
 - (2) a high HLB surfactant; and
 - (3) an aqueous phase
- lie within the shaded region of any one of Figures 2 to 7.
9. A microemulsion as claimed in any one of claims 1 to 8 for use in therapy.
10. A stable, self-emulsifying water-in-oil microemulsion comprising:
- (a) a lipophilic phase having a long-chain fatty acid triglyceride and a low HLB surfactant;
 - (b) a high HLB surfactant; and
 - (c) an aqueous hydrophilic phase
- in which each of (a), (b) and (c) are as defined in any one of claims 2 to 5, 7 or 8 .

1/4




Figure 1

SUBSTITUTE SHEET

$$\left| \frac{\text{Soybean oil}}{\text{Myverol 18-99}} \right| = \frac{3}{1}$$




Figure 3

$$\left| \frac{\text{Soybean oil}}{\text{Myverol 18-99}} \right| = \frac{3}{1}$$




Figure 2

$$\left| \frac{\text{Soybean oil}}{\text{Sorbitan sesquioleate}} \right| = \frac{3}{1}$$




Figure 5

$$\left| \frac{\text{Soybean oil}}{\text{Arlacel 186}} \right| = \frac{3}{1}$$




Figure 4

$$\left| \frac{\text{Soybean oil}}{\text{Sorbitan monooleate}} \right| = \frac{4}{1}$$




Figure 7

$$\left| \frac{\text{Soybean oil}}{\text{Sorbitan monooleate}} \right| = \frac{3}{1}$$




Figure 6

INTERNATIONAL SEARCH REPORT

PCT/US 92/06181

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC
 Int.Cl. 5 A61K9/107

II. FIELDS SEARCHEDMinimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl. 5

A61K

Documentation Searched other than Minimum Documentation
 to the Extent that such Documents are Included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,0 278 660 (STIEFEL LABORATORIES (IRELAND) LIMITED) 17 August 1988	1-5, 7, 9-10
Y	see claims 1,2,4,8-10 see page 3, line 1 - line 14 see page 3, line 40 - line 50 -----	6
Y	FR,A,1 603 312 (NATIONAL RESEARCH DEVELOPMENT CORPORATION) 5 April 1971 see page 1, line 28 - line 32 see page 2, line 1 - line 5 see page 3, line 34 - line 36 see example 1 -----	6

* Special categories of cited documents :¹⁰

* "A" document defining the general state of the art which is not considered to be of particular relevance

* "E" earlier document but published on or after the international filing date

* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

* "O" document referring to an oral disclosure, use, exhibition or other means

* "P" document published prior to the international filing date but later than the priority date claimed

* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* "A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

21 OCTOBER 1992

Date of Mailing of this International Search Report

09. 11. 92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

Dagmar Frank

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

**US 9206181
SA 63284**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 21/10/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0278660	17-08-88	BE-A- 1000281	04-10-88

FR-A-1603312	05-04-71	BE-A- 654793	23-04-65
		FR-M- 4083	
		GB-A- 1080994	
		NL-A- 6412206	26-04-65
